OBJECTIVE: Ischaemic stroke is a major cause of morbidity and mortality in elderly men. Our main objective was to examine whether testosterone (T) or dihydrotestosterone (DHT) was associated with incident ischaemic stroke in elderly men. DESIGN: Cohort study. PARTICIPANTS: Elderly men in the Cardiovascular Health Study who had no history of stroke, heart disease or prostate cancer as of 1994 and were followed until December 2010. MEASUREMENTS: Adjudicated ischaemic stroke. RESULTS: Among 1032 men (mean age 76, range 66-97), followed for a median of 10 years, 114 had an incident ischaemic stroke. Total T and free T were not significantly associated with stroke risk, while DHT had a nonlinear association with incident stroke (P = 0·006) in analyses adjusted for stroke risk factors. The lowest risk of stroke was at DHT levels of 50-75 ng/dl, with greater risk of stroke at DHT levels above 75 ng/dl or below 50 ng/dl. Results were unchanged when SHBG was added to the model. Calculated free DHT had an inverse linear association with incident ischaemic stroke with HR 0·77 (95% CI, 0·61, 0·98) per standard deviation in analyses adjusted for stroke risk factors. CONCLUSIONS: Dihydrotestosterone had a nonlinear association with stroke risk in which there was an optimal DHT level associated with the lowest stroke risk. Further studies are needed to confirm these results and to clarify whether there is an optimal androgen range associated with the least risk of adverse outcomes in elderly men.
OBJECTIVE:Ischaemic stroke is a major cause of morbidity and mortality in elderly men. Our main objective was to examine whether testosterone (T) or dihydrotestosterone (DHT) was associated with incident ischaemic stroke in elderly men. DESIGN: Cohort study. PARTICIPANTS: Elderly men in the Cardiovascular Health Study who had no history of stroke, heart disease or prostate cancer as of 1994 and were followed until December 2010. MEASUREMENTS: Adjudicated ischaemic stroke. RESULTS: Among 1032 men (mean age 76, range 66-97), followed for a median of 10 years, 114 had an incident ischaemic stroke. Total T and free T were not significantly associated with stroke risk, while DHT had a nonlinear association with incident stroke (P = 0·006) in analyses adjusted for stroke risk factors. The lowest risk of stroke was at DHT levels of 50-75 ng/dl, with greater risk of stroke at DHT levels above 75 ng/dl or below 50 ng/dl. Results were unchanged when SHBG was added to the model. Calculated free DHT had an inverse linear association with incident ischaemic stroke with HR 0·77 (95% CI, 0·61, 0·98) per standard deviation in analyses adjusted for stroke risk factors. CONCLUSIONS:Dihydrotestosterone had a nonlinear association with stroke risk in which there was an optimal DHT level associated with the lowest stroke risk. Further studies are needed to confirm these results and to clarify whether there is an optimal androgen range associated with the least risk of adverse outcomes in elderly men.
Authors: Zoë Hyde; Paul E Norman; Leon Flicker; Graeme J Hankey; Osvaldo P Almeida; Kieran A McCaul; S A Paul Chubb; Bu B Yeap Journal: J Clin Endocrinol Metab Date: 2011-10-19 Impact factor: 5.958
Authors: Claes Ohlsson; Elizabeth Barrett-Connor; Shalender Bhasin; Eric Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Liesbeth Vandenput; Dan Mellström; Asa Tivesten Journal: J Am Coll Cardiol Date: 2011-10-11 Impact factor: 24.094
Authors: Bu B Yeap; Helman Alfonso; S A Paul Chubb; David J Handelsman; Graeme J Hankey; Paul E Norman; Leon Flicker Journal: J Clin Endocrinol Metab Date: 2012-09-13 Impact factor: 5.958
Authors: Bu B Yeap; Helman Alfonso; S A Paul Chubb; David J Handelsman; Graeme J Hankey; Osvaldo P Almeida; Jonathan Golledge; Paul E Norman; Leon Flicker Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: Judith S Brand; Nicholas J Wareham; Mitch Dowsett; Elizabeth Folkerd; Yvonne T van der Schouw; Robert N Luben; Kay-Tee Khaw Journal: Clin Endocrinol (Oxf) Date: 2011-05 Impact factor: 3.478
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Huanguang Jia; Charles T Sullivan; Sean C McCoy; Joshua F Yarrow; Matthew Morrow; Stephen E Borst Journal: World J Clin Cases Date: 2015-04-16 Impact factor: 1.337
Authors: Michael A Rosenberg; Molly M Shores; Alvin M Matsumoto; Petra Bůžková; Leslie A Lange; Richard A Kronmal; Susan R Heckbert; Kenneth J Mukamal Journal: Clin Cardiol Date: 2018-06-08 Impact factor: 2.882
Authors: M Reza Sadaie; Mehdi Farhoudi; Masumeh Zamanlu; Nasser Aghamohammadzadeh; Atieh Amouzegar; Robert E Rosenbaum; Gary A Thomas Journal: Ther Adv Drug Saf Date: 2018-05-08
Authors: Arthi Thirumalai; Katya B Rubinow; Lori A Cooper; John K Amory; Brett T Marck; Alvin M Matsumoto; Stephanie T Page Journal: Clin Endocrinol (Oxf) Date: 2017-04-26 Impact factor: 3.478